TCGA-A2-A04N-01A-11R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 145
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- ESTROGEN_RESPONSE_EARLY+0.350
- UV_RESPONSE_DN+0.230
- TGF_BETA_SIGNALING+0.220
- ANGIOGENESIS+0.210
- WNT_BETA_CATENIN_SIGNALING+0.200
- ESTROGEN_RESPONSE_LATE+0.120
- APICAL_JUNCTION+0.110
- P53_PATHWAY+0.100
- APICAL_SURFACE+0.090
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.500
- INTERFERON_GAMMA_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- MITOTIC_SPINDLE-0.320
- IL6_JAK_STAT3_SIGNALING-0.270
- INFLAMMATORY_RESPONSE-0.270
- MYC_TARGETS_V1-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66K-01A-11R-A29R-07 | — | B | 0.871 |
| 2 | AUR-AEPZ-TTP1-A-1-1-R-A742-41 | — | B | 0.819 |
| 3 | SRR25617895 | — | B | 0.818 |
| 4 | 20060260.Her2HRpos | — | A | 0.810 |
| 5 | 20030017.LumA | — | B | 0.807 |
| 6 | TCGA-B6-A0RN-01A-12R-A084-07 | — | B | 0.805 |
| 7 | SRR8518225 | — | B | 0.804 |
| 8 | TCGA-E2-A570-01A-11R-A29R-07 | — | B | 0.797 |
| 9 | TCGA-A8-A09B-01A-11R-A00Z-07 | — | B | 0.797 |
| 10 | C3L-02165 | — | cohortA2 | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |